Complete the Fatigue Severity Scale with a minimum score of 36 Exclusion Criteria Certain vulnerable populations (prisoners, children, fetuses, and institutionalized individuals) Women who are pregnant, excluded due to unknown risks to a fetus Personal or family history of medullary thyroid carcinoma History of severe gastrointestinal disease Diagnosis of gastroparesis Worsening or chronic renal failure History of pancreatitis Multiple Endocrine Neoplasia syndrome type 2 Known serious hypersensitivity to tirzepatide Already taking tirzepatide or another GLP-1 agonist Medication contraindications to tirzepatide History of suicidal attempts and/or active suicidal ideation Underweight (BMI under 18.5) Planning to undergo elective surgery or procedures requiring general anesthesia or deep sedation in the next 12 months Symptoms of fatigue and/or brain fog that predated infection with COVID-19 What is approved documentation to verify my diagnosis

The provider confirmed my treatment and sent the prescription to one of IVIMs pharmacy partners
Clinical trials of Wegovy, Mounjaro, and Ozempic showed effectiveness, but potential side effects, including hair loss in 3-6% of patients
Do not inject into bruised, irritated, or painful skin
however, severe or persistent symptoms, such as severe pain, vomiting, or jaundice, require prompt medical attention
Anxiety on tirzepatide is reported by some users, though the relationship between the compound and mood changes is not fully understood